Copy
DAWN CH Clinical Haematology Software Newsletter

January 2016 DAWN Haematology Software E-Newsletter
In this issue:
DAWN Messaging - Promoting effective healthcare team communication
Communication tools in DAWN CH are designed to enable you to effectively communicate information and coordinate team activities to provide safe patient care.

Features of messaging within DAWN CH include:
  • Quick notes - Most recent note recorded at the top
  • Electronic referrals - quicly and easily refer patients
  • Categorised messages - Letters section, filtered by HCP role
  • Visibility - Time, date, and person stamped, type of message
  • Accessibility - Viewable by all staff
  • Accountability - Sign off that task has been completed, record of who and when this task was completed
You can use the message centre to communicate between team members rather than sending each other emails, being flooded with emails and potentially losing track of them.

For more information about DAWN CH and its communication tools, contact the 4S DAWN team today at sales@4s-dawn.com.


Why results are highlighted red in the history panel
 

 
Results shown in red in the history panel fall outside action limits or a trend was set and exceeded for these tests.

Information on results highlighted red:
  • Only results associated with an active treatment plan and a current visit or appointment can be checked for trends or limits
  • A result above or below a limit will have a red colour and a chevron symbol shown (<< < > >>)
  • A result triggering one of the trend settings for this test will have a small chart symbol and a percentage change over the number of results examined
  • A result is red with no symbol if a previous result warning is linked to the result
  • A result may be red with no symbol if the change percentage threshold is exceeded from the previous result. The change percentage threshold is 10% by default but is often set higher for some tests.

Recommendations for your DAWN system: live and test
Ideally you should not have two DAWN systems sharing the same web server as they share some application files such as the runtime DLL’s.  As a consequence, upgrades must be applied two both systems at exactly the same time.  

This rules out having a live and test server on the same machine as you cannot use the test system to test an upgrade ahead of applying it to the live. 
For further information contact the 4S DAWN support team at support@4s-dawn.com


DAWN CH enables monitoring of a wide range of haematological disorders
DAWN CH, Clinical Haematology software is designed to help manage the long-term therapy of stable patients with a range of haematological disorders including Myeloproliferative Disease (MPD), Haemochromatosis, Monoclonal Gammopathy of Unknown Significance (MGUS), Stable
Chronic Leukemia, and Idiopathic Thrombocytopenic Purpura (ITP).

DAWN CH is a comprehensive but easy-to-use software package that helps alleviate the key frustrations of monitoring long-term patients.
  • Easy and transparent cytotoxic drug dosing
  • All the information is available on one screen
  • Improved efficiency and productivity
  • Configurable screens to fit your workflow
  • Powerful reporting facility
  • Audit patient records easily
For more information visit the Clinical Haematology page of the 4S DAWN website or contact the 4S DAWN team at sales@4s-dawn.com or 015395 63091 who will be happy to answer any questions or provide an online demonstration of the DAWN CH system.


Did you know...

Ofatumumab Approved as Maintenance Therapy for CLL
The US Food and Drug Administration (FDA) granted approval to the CD20-targeting monoclonal antibody ofatumumab (Arzerra) for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia (CLL) who are in complete or partial remission after two or more lines of prior therapy.

This approval was based on clinical trials results that showed that patients with CLL assigned maintenance therapy with ofatumumab had close to double the progression-free survival (PFS) compared with patients who did not undergo maintenance therapy.
http://www.cancernetwork.com/leukemia-lymphoma/ofatumumab-approved-maintenance-therapy-cll

Risk Factors for Fatigue in Patients With Myeloproliferative Neoplasms Assessed
Management of fatigue in patients treated for myeloproliferative neoplasms (MPNs) should include a comprehensive assessment and treatment plan in order to address modifiable etiologies, according to a recent study published online ahead of print in Cancer.

Robyn Scherber MD, MPH, of the Mayo Clinic in Scottsdale, AZ, developed a 70-item, Internet-based survey regarding fatigue that was hosted by the Mayo Clinic Survey Research Center
http://www.cancertherapyadvisor.com/hematologic-cancers/myeloproliferative-neoplasm-mpn-fatigue-risk-factor-treatment-risk/article/460067/

Prognostic Factors and the Impact of New Therapies
The availability of new monoclonal antibodies and novel targeted therapies for chronic lymphocytic leukemia has greatly increased the complexity of treating symptomatic patients. This discussion is designed to shed some light on the latest data coming out of ASH 2015, and how this new information will affect how we treat our patients with CLL.
http://global.onclive.com/peer-exchange/chronic-lymphocytic-leukemia/prognostic-factors-and-the-impact-of-new-therapies-







Follow us on our LinkedIn Page!
4S DAWN Clinical Software has a new LinkedIn company page where you can keep up to date with all of the latest news and developments. Follow us and join our LinkedIn community: CLICK HERE
 

 
Copyright © 2016 4S Information Systems Ltd, All rights reserved.